Clinical Trial

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

Name: Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight — clinical trial record (NCT07046182)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

To observe the efficacy and safety of the CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma.

Trial Details

NCT Number	NCT07046182
Lead Sponsor	Zhengzhou University
Conditions	Angioimmunoblastic T-cell Lymphoma (AITL)
Enrollment	34 participants
Start Date	2023-10-21
Primary Completion	2028-05-26 (estimated)
Study Completion	2028-05-26 (estimated)
Updated on ClinicalTrials.gov	2025-07-01